Consistent with this idea, treatment with CES1 inhibitors effectively killed human CRC cells upon glucose limitation and markedly impaired CRC growth without apparent adverse effects in mouse allograft and xenograft models [258,259,260]. This evidence concerns the gene CES1 and colorectal carcinoma.